---
title: 'Life Sciences Daily Summary: What Happened on October 31, 2026'
headline: FDA advisers back another trial for Sydnexis’ pediatric myopia drug
description: The panel questioned whether existing trial results show a meaningful
  benefit from low-dose atropine, despite the treatment meeting prespecified endpoints.
url: https://thebench.bio/news/summaries/2026-10-31
topic: all
date: '2026-10-31'
covers:
- '2026-10-31'
date_published: '2026-10-31T12:01:14Z'
date_modified: '2026-10-31T12:01:14Z'
tags:
- Regulatory
sources: 1
publisher: TheBench.Bio
---

# Life Sciences Daily Summary: What Happened on October 31, 2026

**FDA advisers back another trial for Sydnexis’ pediatric myopia drug**

The panel questioned whether existing trial results show a meaningful benefit from low-dose atropine, despite the treatment meeting prespecified endpoints.

## Today in brief

An FDA advisory panel favored another trial of Sydnexis’ low-dose atropine treatment for children with myopia. [1]

## FDA advisers want more evidence for Sydnexis drug

The panel favored another trial to establish whether Sydnexis’ SYD-101 provides a meaningful benefit in pediatric myopia. [1] The FDA had issued the company a complete response letter, citing inadequate evidence of effectiveness, although the lower dose met the Phase III STAR trial’s prespecified endpoints. [1]

## Sources

1. [Widespread atropine use fails to sway FDA advisors on Sydnexis data](<https://www.biocentury.com/article/661385/widespread-atropine-use-fails-to-sway-fda-advisors-on-sydnexis-data?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-10-31

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.biocentury.com/article/661385/widespread-atropine-use-fails-to-sway-fda-advisors-on-sydnexis-data?utm_source=bc_rss&utm_medium=rss>